On September 17, 2020 InnoCare Pharmaceuticals (HKEX: 09969), a clinical stage biopharmaceutical company committed to discovering, developing, and commercializing innovative medicines for the treatment of cancer and autoimmune diseases, reported that the company will present at the upcoming Morgan Stanley 2020 Virtual Asia Pacific Conference and ZGC Forum (Press release, InnoCare Pharma, SEP 17, 2020, View Source [SID1234565304]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

InnoCare CFO, Mr. Shaojing Tong, will join the China Biotech Panel of the Morgan Stanley conference to discuss and share the insights of China’s booming biotech industry on Thursday, September 24, 2020 China time.

Meanwhile, InnoCare will exhibit innovative medicine at the ZGC forum from September 17-20 in Beijing. Dr. Renbin Zhao, Executive Director of Biology and Clinical Development Strategy of InnoCare will present on the latest development of BTK inhibitor Orelabrutinib on the afternoon of Thursday, September 17, 2020, China time.

Founded in 2007, the ZGC forum has been held for years with the mission to promote communication, exchange, and cooperation in the field of science and technology worldwide.